2160.HK (HKSE) MicroPort CardioFlow HK$3.46 after-hours 10 Mar 2026: Watch RSI

2160.HK stock moved sharply in after-hours trade on 10 Mar 2026, closing at HK$3.46 on heavy volume. The session recorded 652,600.00 shares traded, with a relative volume of 7.87. The jump followed sector chatter and comparison screens. Traders should note the stock’s high momentum and stretched technicals as we link news, fundamentals, and forecasts for MicroPort CardioFlow Medtech Corporation on the HKSE in Hong Kong.

Price action and high volume for 2160.HK stock

MicroPort CardioFlow (2160.HK) posted an after-hours price of HK$3.46 with a one-day change of HK$2.62. Volume reached 652,600.00 shares, far above the 1,628,336.00 average. The stock opened at HK$3.51 and traded between HK$3.31 and HK$3.51 today. This surge made 2160.HK a clear high-volume mover on the HKSE, attracting momentum traders.

Drivers and recent news that moved 2160.HK stock

There is no company press release today. Market sources show competitor comparison flows and sector screens that likely triggered buying interest. See comparison pages on Investing.com for context source and source. Market chatter paired with low float dynamics explains the outsized percentage move.

Fundamentals and valuation snapshot for MicroPort CardioFlow (HKSE)

Key company metrics show EPS 0.02 and a reported PE of 41.00. Price-to-book is low at 0.15, and cash per share is HK$2.83. Market cap stands near HK$395,696,440.00 with 482,556,634.00 shares outstanding. The current ratio is 6.94, reflecting a strong liquidity cushion. These figures point to a capital-heavy medtech with mixed profitability metrics.

Technicals and momentum indicators behind the high-volume move

Technicals show strong momentum. RSI sits at 77.36, flagged as overbought. MACD is positive with histogram strength, and ADX at 48.68 signals a strong trend. The stock’s relative volume and ROC point to aggressive short-term interest. Traders should watch intraday support at HK$3.31 and resistance near HK$3.51.

Meyka AI grade and model forecast for 2160.HK stock

Meyka AI rates 2160.HK with a score out of 100. Meyka AI assigns a score of 68.26 giving a Grade: B and a Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a one-year price of HK$1.06. Compared with the current HK$3.46, that implies an estimated downside of -69.48%. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors.

Risks, opportunities and short-term trading ideas

Opportunities include medical device demand in China and a low PB of 0.15 for asset backing. Risks include stretched technicals, limited analyst coverage, and a thin trading float that can amplify swings. Short-term traders may use tight stops under HK$3.31. Longer-term investors should weigh R&D intensity and cash per share before adding exposure.

Final Thoughts

2160.HK stock posted a clear high-volume after-hours move to HK$3.46 on 10 Mar 2026 in Hong Kong. The spike came with high relative volume 7.87, an overbought RSI 77.36, and mixed fundamentals that show liquidity but modest earnings power. Meyka AI’s forecast model projects a one-year target of HK$1.06, implying a -69.48% downside from today’s price. Our internal scenarios place a conservative near-term target at HK$3.00, a base case at HK$1.06, and a bullish recovery target at HK$6.00 if clinical or commercial news improves. Given the grade B and a HOLD suggestion, traders should treat the stock as volatile. For quick trades, use technical support and volume confirmation. For longer investors, wait for clearer earnings or regulatory catalysts. Meyka AI, an AI-powered market analysis platform, flags the current move as volume-driven and technically stretched, not yet validated by new company fundamentals.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.